KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™

Published Apr 08 2021 at 8:05 PM GMT
  • Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million, and Adds a New Top-Level Tier for Royalties on US Net SalesConference Call and Live Audio Webcast.


  • Published Apr 8, 2021 8:05 PM GMT